A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 451
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : CR
Long Form : controlled-release
No. Year Title Co-occurring Abbreviation
2020 Amphiphilic polymer based nanoformulations of mancozeb for management of early blight in tomato. ---
2020 Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization. ADF, CI, ER, HCl, OR
2020 Beneficial Effect of Flecainide Controlled Release on the Quality of Life of Patients with Atrial Fibrillation-the REFLEC-CR Study. AF, CCS-SAF, PerAF, QOL
2020 Controlled Release of Oxycodone as an Opioid Titration for Cancer Pain Relief: A Retrospective Study. GPM, IR, NRS
2020 Effect of Roux-en-Y gastric bypass on the bioavailability of metoprolol from immediate and controlled release tablets: a single oral dose study before and after surgery. AUC, IR, RYGB
2020 Efficacy and safety of short-term use of a pelubiprofen CR and aceclofenac in patients with symptomatic knee osteoarthritis: A double-blinded, randomized, multicenter, active drug comparative, parallel-group, phase IV, non-inferiority clinical trial. K-WOMAC, VAS
2020 Oral controlled release dosage forms: dissolution versus diffusion. API, GI, IR, PK
2020 Patterns of oxycodone controlled release use in older people with cancer following public subsidy of oxycodone/naloxone formulations: An Australian population-based study. DVA
2020 Preparation and characterization of metformin hydrochloride controlled-release tablet using fatty acid coated granules. ALS, MFM, MFM-CRT, micro-CT, PEO
10  2020 Risk factors of infective endocarditis in persons who inject drugs. IE, PWID
11  2020 Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development. BCS, GIT, IR, PAMPA
12  2020 Tapentadol vs oxycodone for postoperative pain treatment the first 7 days after total knee arthroplasty: a randomized clinical trial. ER, IQR
13  2019 A gastrointestinal simulation system for dissolution of oral solid dosage forms before and after Roux-en-Y gastric bypass. GISS, IR, RYGB
14  2019 Bayesian knowledge integration for an in vitro-in vivo correlation model. IR, IVIVC, ODEs, PK, TD
15  2019 Development and evaluation of dexibuprofen formulation with fast onset and prolonged effect. HPMC, SLS
16  2019 Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study. RD
17  2019 Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study. CPRD, HES, IRRs, PR
18  2019 Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products. BE, GI, IR
19  2019 Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients. UC
20  2019 Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? IBS, IBS-D, IBS-QOL, NoBM7d, OPD
21  2018 A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD, CGI-I, HR, MINI
22  2018 Cebranopadol: A Novel, First-in-Class, Strong Analgesic: Results from a Randomized Phase IIa Clinical Trial in Postoperative Acute Pain. IMP, NOP, SPI, TEAE
23  2018 Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study. ADRs, CGI-S, IR, MDD
24  2018 Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials. OA, PR
25  2018 Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review. ---
26  2018 Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet. AEs, CIs, GMRs, IR, PK
27  2018 Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia. CI, HR, IRR, OR
28  2018 PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen. NPs, PLGA
29  2018 Preclinical models for colonic absorption, application to controlled release formulation development. ---
30  2017 An innovative method for the preparation of high API-loaded hollow spherical granules for use in controlled-release formulation. API, PSD
31  2017 Assessing the impact of prescribing directives on opioid prescribing practices among Veterans Health Administration providers. FDA, VHA
32  2017 Blend Hydrogel Microspheres of Carboxymethyl Chitosan and Gelatin for the Controlled Release of 5-Fluorouracil. 5-FU, CMCS, DSC, FTIR, GA, GE, SEM, XRD
33  2017 Clinical evaluation of ropinirole controlled-release formulation at 18-24mg/day in Japanese patients with Parkinson's disease. ---
34  2017 Comparison of ambulatory blood pressure-lowering effects of higher doses of different calcium antagonists in uncontrolled hypertension: the Calcium Antagonist Controlled-Release High-Dose Therapy in Uncontrolled Refractory Hypertensive Patients (CARILLON) Study. BP, CARILLON
35  2017 Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. CD-LD, IR, PD
36  2017 Dialyzability of Oxycodone and Its Metabolites in Chronic Noncancer Pain Patients with End-Stage Renal Disease. HD, HDF
37  2017 Efficacy and Safety of Different Aceclofenac Treatments for Chronic Lower Back Pain: Prospective, Randomized, Single Center, Open-Label Clinical Trials. CLBP, EQ-5D, ODI, VAS
38  2017 Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients With Postherpetic Neuralgia: A Double-Blind, Enriched Enrollment Randomized Withdrawal, Placebo-Controlled Trial. LTR
39  2017 Interleukin-6 increases the expression of key proteins associated with steroidogenesis in human NCI-H295R adrenocortical cells. AP-1, IL-6, JAK, SE, SF-1, StAR, STAT
40  2017 Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms. IR
41  2017 Nanomedicine for prostate cancer using nanoemulsion: A review. NE, PCa
42  2017 Oxycodone for cancer-related pain. CENTRAL, CI, IR, RR, SMD
43  2017 Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects
. ---
44  2017 Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study. LS, PR
45  2016 Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine. DM, MRDM/DX, MRs
46  2016 Controlled release drug delivery systems to improve post-operative pharmacotherapy. LAs, NSAIDs
47  2016 Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada. OIC, QALYs
48  2016 Eco-friendly PEG-based controlled release nano-formulations of Mancozeb: Synthesis and bioefficacy evaluation against phytopathogenic fungi Alternaria solani and Sclerotium rolfsii. ED50, PEGs
49  2016 Effects of Zolpidem CR on Sleep and Nocturnal Ventilation in Patients with Heart Failure. AHI
50  2016 Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. DB, FDA, NGF, OA, OAPI
51  2016 Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release-Using criteria of health technology assessment. HRQoL, MID, PR, RR
52  2016 The Adverse Events of Oxycodone in Cancer-Related Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. AEs, CIs, Mc, RR
53  2016 The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles. MSNs
54  2016 Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption. IR, PBPK
55  2015 "Rolling" phenomenon in twin screw granulation with controlled-release excipients. ---
56  2015 A Retrospective, Pooled Suicidality Evaluation of Ropinirole Immediate Release and Controlled Release for the Treatment of Restless Legs Syndrome. IR, RLS
57  2015 Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. AUC, IR, PBPK
58  2015 Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human. IR, PBPK, PK
59  2015 Controlled release of therapeutics using interpenetrating polymeric networks. IPN
60  2015 Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets. HPMC
61  2015 Development and preliminary validation of an integrated efficacy-tolerability composite measure for the evaluation of analgesics. AEs, ER, ETC
62  2015 Development of controlled release nanoformulations of carbendazim employing amphiphilic polymers and their bioefficacy evaluation against Rhizoctonia solani. PEGs, POA, WP
63  2015 Effect of the gastrointestinal prokinetic agent erythromycin on the pharmacokinetics of pregabalin controlled-release in healthy individuals: a phase I, randomized crossover trial. ---
64  2015 Electrospun nanofibers as a potential controlled-release solid dispersion system for poorly water-soluble drugs. DSC, HPMC, PRX, SD, SEM, XPRD
65  2015 In Situ Perfusion Model in Rat Colon for Drug Absorption Studies: Comparison with Small Intestine and Caco-2 Cell Model. Fa
66  2015 Long-term safety and efficacy of high-dose controlled-release nifedipine (80 mg per day) in Japanese patients with essential hypertension. BID, BP, CCB
67  2015 Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial. ER
68  2015 Multiple-Dose Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety in Healthy Subjects: A Comparison of Controlled-Release Sarpogrelate and Immediate-Release Sarpogrelate. IR
69  2015 Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain. OFL, TD
70  2015 Oxycodone for cancer-related pain. CENTRAL, CI, ICTRP, IR, mRCT, SMD
71  2015 Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone. CCSD
72  2015 Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depression. CGI-GI, CGI-SI, CI
73  2015 Successful interventions in decreasing oxycodone CR prescriptions within an underserved population. ---
74  2015 Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain. ER, TEAEs
75  2014 Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. PBPK, PDs, PKs
76  2014 Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. ADF, CI, ER, RR
77  2014 Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. CNS, ER, GE, QALY, RCTs
78  2014 Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of immediate-release simvastatin in chronic kidney disease patients with dyslipidemia. CKD, IR
79  2014 Controlled release of therapeutic antibody formats. CNS
80  2014 Controlled-release oxycodone versus naproxen at home after ambulatory surgery: a randomized controlled trial. ---
81  2014 Design, in vitro release characterization and pharmacokinetics of novel controlled release pellets containing levodropropizine. IR, LDP, SR
82  2014 Development of Process Analytical Technology (PAT) methods for controlled release pellet coating. API, CQAs, NIR, PAT, QbD
83  2014 Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. ---
84  2014 Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study. IR, KOOS, OA, ROM, VAS
85  2014 Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. CRC, OIPN
86  2014 Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. bpm, DBP, ER, SBP, SE
87  2014 Guar gum as platform for the oral controlled release of therapeutics. GG
88  2014 Influence of formulation on mobility of metazachlor in soil. SC
89  2014 Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study. BP, DBP
90  2014 Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. AE, LTR
91  2014 Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. IR
92  2014 Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. AUC24, IR
93  2014 Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. AEs, ER, HCl, TEAE
94  2014 Study the effect of formulation variables on drug release from hydrophilic matrix tablets of milnacipran and prediction of in-vivo plasma profile. DE, HPMC, MDT, MRT
95  2014 Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. CI, OR, PR, TEAEs
96  2014 The controlled release of bioactive compounds from lignin and lignin-based biopolymer matrices. ---
97  2013 A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain. BMI, ER
98  2013 A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy. DN
99  2013 Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users. MSN, PK
100  2013 Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain. ER, OISEs, PMPM